Sort by

Send to

Choose Destination

Links from PubMed

Items: 16


Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.

Kuoppamäki M, Leinonen M, Poewe W.

J Neural Transm (Vienna). 2015 Dec;122(12):1709-14. doi: 10.1007/s00702-015-1449-6.


Time to change the blind men and the elephant approach to Parkinson disease?

Racette BA, Willis AW.

Neurology. 2015 Jul 14;85(2):190-6. doi: 10.1212/WNL.0000000000001739. Review.


Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.

Pistacchi M, Martinello F, Gioulis M, Zambito Marsala S.

Neurol Ther. 2013 Dec 17;3(1):41-66. doi: 10.1007/s40120-013-0014-1. Review.


Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, Tsurkalenko ES, Kell S, Hsu A, Khanna S, Gupta S.

CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2.


Treatment of Parkinson's disease in the advanced stage.

Ossig C, Reichmann H.

J Neural Transm (Vienna). 2013 Apr;120(4):523-9. doi: 10.1007/s00702-013-1008-y. Review.


Motor fluctuations and dyskinesias (diagnosis and management).

[No authors listed]

Ann Indian Acad Neurol. 2011 Jul;14(Suppl 1):S13-5. No abstract available.


Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F.

Clin Interv Aging. 2010 Sep 7;5:229-38. Review.


Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Choonara YE, Pillay V, du Toit LC, Modi G, Naidoo D, Ndesendo VM, Sibambo SR.

Int J Mol Sci. 2009 Jun 3;10(6):2510-57. doi: 10.3390/ijms10062510. Review.


One-year open-label study of entacapone in patients with advanced Parkinson disease.

Ahn TB, Im JH, Lee MC, Kim JW, Lee WY, Jeon BS.

J Clin Neurol. 2007 Jun;3(2):82-5. doi: 10.3988/jcn.2007.3.2.82.


Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD; CSP 468 Study Group..

JAMA. 2009 Jan 7;301(1):63-73. doi: 10.1001/jama.2008.929.


Minority enrollment in Parkinson's disease clinical trials.

Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC.

Parkinsonism Relat Disord. 2009 May;15(4):258-62. doi: 10.1016/j.parkreldis.2008.06.005.


Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K.

Br J Clin Pharmacol. 2002 Oct;54(4):363-71.

Items per page

Supplemental Content

Support Center